Steven M. Bair

Hematology

1665 Aurora Ct
Aurora, CO 80045

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Feasibility and Safety of a Novel CD19-Directed CAR T-Cell Therapy in Patients with R/R B-Cell Non-Hodgkin Lymphoma.

Feasibility and Safety of a Novel CD19-Directed CAR T-Cell Therapy in Patients with R/R B-Cell Non-Hodgkin Lymphoma.

Journal: Transplantation and cellular therapy

Published: February 23, 2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Journal: Blood advances

Published: February 23, 2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Journal: Blood advances

Published: February 23, 2026

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma.

Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma.

Journal: Blood cancer journal

Published: December 22, 2025

Ganciclovir-resistant CMV encephalitis in a mantle cell lymphoma patient on pirtobrutinib: Case report.

Ganciclovir-resistant CMV encephalitis in a mantle cell lymphoma patient on pirtobrutinib: Case report.

Journal: IDCases

Published: May 04, 2025

Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling.

Navigating the landscape of personalized oncology: overcoming challenges and expanding horizons with computational modeling.

Journal: Journal of the American Medical Informatics Association : JAMIA

Published: August 30, 2024

Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.

Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers.

Journal: Haematologica

Published: June 06, 2024

DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas.

DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 03, 2024

Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy.

Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy.

Journal: Clinical lymphoma, myeloma & leukemia

Published: March 02, 2024

Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.

Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.

Journal: Blood advances

Published: August 25, 2023

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.

Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.

Journal: Blood advances

Published: May 12, 2023

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.

Journal: Blood advances

Published: May 03, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026